Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Emergence of extensive drug resistance (XDR) among Gram-negative bacilli in South Africa looms nearer.

Brink A, Feldman C, Richards G, Moolman J, Senekal M.

S Afr Med J. 2008 Aug;98(8):586, 588, 590 passim. No abstract available.

PMID:
18928032
2.

Enteric gram-negative bacilli bloodstream infections: 17 years' experience in a neonatal intensive care unit.

Cordero L, Rau R, Taylor D, Ayers LW.

Am J Infect Control. 2004 Jun;32(4):189-95.

PMID:
15175611
4.

Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Giske CG, Monnet DL, Cars O, Carmeli Y; ReAct-Action on Antibiotic Resistance.

Antimicrob Agents Chemother. 2008 Mar;52(3):813-21. Epub 2007 Dec 10. Review. No abstract available.

5.
6.

[Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].

Gür D, Gülay Z, Akan OA, Aktaş Z, Kayacan CB, Cakici O, Eraç B, Gültekin M, Oğünç D, Söyletir G, Unal N, Uysal S.

Mikrobiyol Bul. 2008 Oct;42(4):537-44. Turkish.

PMID:
19149074
7.

Antimicrobial susceptibility pattern and epidemiology of female urinary tract infections in South Korea, 2010-2011.

Lee DS, Choe HS, Lee SJ, Bae WJ, Cho HJ, Yoon BI, Cho YH, Han CH, Jang H, Park SB, Cho WJ, Lee SJ.

Antimicrob Agents Chemother. 2013 Nov;57(11):5384-93. doi: 10.1128/AAC.00065-13. Epub 2013 Aug 19.

8.

Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe.

Souli M, Galani I, Giamarellou H.

Euro Surveill. 2008 Nov 20;13(47). pii: 19045. Review.

9.

Long-term study of Escherichia coli and Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases.

Polwichai P, Trakulsomboon S, Dejsirilert S, Thongmali O, Sawanpanyalert P, Aswapokee N, Buppanharun W.

J Med Assoc Thai. 2009 Aug;92 Suppl 4:S53-8.

PMID:
21294502
11.
12.

Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.

Sahm DF, Critchley IA, Kelly LJ, Karlowsky JA, Mayfield DC, Thornsberry C, Mauriz YR, Kahn J.

Antimicrob Agents Chemother. 2001 Jan;45(1):267-74.

13.

Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods.

Hombach M, Wolfensberger A, Kuster SP, Böttger EC.

J Clin Microbiol. 2013 Jul;51(7):2385-7. doi: 10.1128/JCM.00921-13. Epub 2013 Apr 17.

14.

A step closer to extreme drug resistance (XDR) in gram-negative bacilli.

Paterson DL, Doi Y.

Clin Infect Dis. 2007 Nov 1;45(9):1179-81. Epub 2007 Sep 27. No abstract available.

PMID:
17918079
15.

[What does ESBL mean?].

Kaase M, Kern WV.

Dtsch Med Wochenschr. 2012 Oct;137(40):2010-3. Epub 2012 Sep 28. Review. German. No abstract available.

PMID:
23023611
16.

Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010).

Cantón R, Loza E, Aznar J, Calvo J, Cercenado E, Cisterna R, Romo FG, Hontangas JL, Calvo CR, Barrenechea AI, Tubau F, Weber I, Yuste P, Cavanillas R; SMART-Spain Working Group.

Rev Esp Quimioter. 2011 Dec;24(4):223-32.

17.

Amifloxacin activity against well-defined gentamicin-resistant, gram-negative bacteria.

John JF Jr, Twitty JA.

Antimicrob Agents Chemother. 1984 Nov;26(5):781-4.

18.

Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora.

Richard P, Delangle MH, Raffi F, Espaze E, Richet H.

Clin Infect Dis. 2001 Jan;32(1):162-6. Epub 2000 Dec 11.

PMID:
11112677
20.

Supplemental Content

Support Center